TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21114535
Drug: YSPSL (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: YSPSL (recombinant P-selectin glycoprotein ligand Ig) administered systemically to the recipient pre-reperfusion.
Study: 21114535
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no YSPSL treatment).
Study: 20133269
Drug: Initial antiretroviral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antiretroviral therapy with resistance mutations at baseline
Study: 20133269
Drug: Initial antiretroviral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antiretroviral therapy without resistance mutations at baseline
Study: 15559222
Drug: Cerebrolysin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 10 ml/d
Study: 15559222
Drug: Cerebrolysin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 50 ml/d
Study: 7566576
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg/day per os)
Study: 2132299
Drug: Keto acids
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keto acids treatment for 12 months
Study: 377154
Drug: Ibuprofen 400mg
Normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg t.d.s.
Study: 30630671
Drug: 62.5 mg
Normalized name: quinine 162.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5 mg acetazolamide twice daily
Study: 30630671
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg acetazolamide twice daily
Study: 28072446
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg administered intravenously 30 minutes before surgery
Study: 20704622
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg courses, two doses with a 15-day interval)
Study: 20704622
Drug: Cytotoxic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic combination therapy (pulse cyclophosphamide 1000 mg/monthly, azathioprine 2-3 mg/kg per day, and prednisolone 0.5 mg/kg per day)
Study: 20704622
Drug: Cytotoxic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic combination therapy
Study: 16295703
Drug: Quit and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quit and Win contest (30-day quit period, provider advice via weekly mailings, online and telephone quit assistance, media campaign, community support)
Study: 9255754
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily for 1 year
Study: 3830248
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin suppository administered at 9.00 hours
Study: 3830248
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin suppository administered at 21.00 hours
Study: 30209962
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg/h)
Study: 30209962
Drug: Control (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Continuous propofol infusion and fentanyl boluses)
Study: 30209962
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/kg/h)
Study: 27428384
Drug: Soap and
Normalized name: Green soap and industrial methylated spirit only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soap and water bathing daily
Study: 16206355
Drug: Milnacipran twice
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran twice daily
Study: 16206355
Drug: Milnacipran once
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran once daily
Study: 7575711
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 0.3 mg/day
Study: 7575711
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 1.0 mg/day
Study: 7575711
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 3.0 mg/day
Study: 7575711
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 10.0 mg/day
Study: 7575711
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 30.0 mg/day
Study: 26749079
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation
Study: 23139071
Drug: Adjunctive photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive photodynamic therapy using LED light (Fotosan) with toluidine blue O solution
Study: 15134608
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) using the Dornier Epos Ultra, single therapy session
Study: 15134608
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Control Group)
Study: 8083130
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (7 Gy single fraction administered < 4 h before surgery)
Study: 8083130
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (5 fractions of 3.5 Gy, total dose 17.5 Gy administered < 72 h after surgery)
Study: 8452170
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for 7 days
Study: 2511802
Drug: Fleroxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (600 or 800 mg) once daily for 7 days
Study: 765518
Drug: Trimethoprim-sulfamethoxazole (trimethoprim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours)
Study: 765518
Drug: Ampicillin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (100 mg/kg/day administered in divided doses every six hours)
Study: 24528807
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) 220kcal
Study: 19541503
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (control)
Study: 22845008
Drug: BAF312 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAF312 dose titration regimen DT1 (0.25-10 mg over 9-10 days)
Study: 22845008
Drug: BAF312 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAF312 dose titration regimen DT2 (0.25-10 mg over 9-10 days)
Study: 22845008
Drug: BAF312 non-titration
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAF312 non-titration regimen (10 mg starting dose)
Study: 20975325
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT-G)
Study: 20975325
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment (either Sertraline or CBT-G)
Study: 12888778
Drug: ketamine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.1 mg/kg
Study: 8967639
Drug: Anti-HAV (IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HAV (IgG antibodies against hepatitis A virus)
Study: 8967639
Drug: Anti-HBc (antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HBc (antibodies against hepatitis B virus core antigen)
Study: 8967639
Drug: Anti-HCV (antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HCV (antibodies against hepatitis C virus)
Study: 8967639
Drug: Anti-HEV (antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HEV (antibodies against hepatitis E virus)
Study: 2932814
Drug: Bronchodilator (salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (salbutamol 5 mg)
Study: 2932814
Drug: Bronchodilator (ipratropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (ipratropium 1 mg)
Study: 26918314
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment for Class I malocclusions
Study: 24934787
Drug: Single-agent paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent paclitaxel (T)
Study: 18512312
Drug: L‐asparaginase (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐asparaginase (6000 IU/m2, three times a week for 2 weeks) in VDLP regimen
Study: 10343464
Drug: Self-administered PASI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered PASI (SAPASI)
Study: 25899896
Drug: Ginger (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (2-g ginger rhizomes powder as two 1-g tablets per day)
Study: 21215809
Drug: Intravenous busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous busulfan (3.2 mg/kg/day)
Study: 15504987
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (4 x 40 IU/day)
Study: 3315535
Drug: Esaprazole 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaprazole 900 mg/day
Study: 3315535
Drug: Esaprazole 1350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaprazole 1350 mg/day
Study: 28902035
Drug: Small-particle hyaluronic
Normalized name: Smallanthus sonchifolius whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-particle hyaluronic acid (SPHA) injectable gel
Study: 15156935
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (2 g daily for 6 months)
Study: 23276892
Drug: Preoperative PTCD
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative PTCD with bile re‐infusion (n = 56)
Study: 23276892
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment alone (n = 60)
Study: 10792556
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - transdermal application of continuous 17-beta oestradiol with cyclic medroxyprogesterone acetate tablets every 3rd month for 14 days
Study: 10792556
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - sequential administration of medroxyprogesterone acetate
Study: 10792556
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - during medroxyprogesterone administration
Study: 9065187
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg
Study: 9065187
Drug: Gestrinone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 1.25 mg
Study: 27449527
Drug: G + MH intervention
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G + MH intervention (mental health Internet interventions + gambling intervention)
Study: 27449527
Drug: G‐only intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐only intervention (gambling intervention only)
Study: 24231016
Drug: Test food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test food containing 300 mg calcium, 150 mg magnesium, and 4.0 g lactulose
Study: 19016185
Drug: Jinniu capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinniu capsules
Study: 11111143
Drug: Slow-release twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow-release twice-daily nifedipine
Study: 11111143
Drug: Nifedipine (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (without specifying dosage or duration)
Study: 24995890
Drug: Adjunctive edivoxetine
Normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive edivoxetine (6-18 mg once daily)
Study: 21050498
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiation therapy (60 Gy E ± 5%)
Study: 21050498
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation therapy (70 Gy E ± 5%)
Study: 21050498
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiation therapy
Study: 21050498
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation therapy
Study: 9083709
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (immediately before each meal)
Study: 9083709
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (30 to 45 minutes before eating)
Study: 1976052
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cimetidine
Study: 3993320
Drug: Bupivacaine (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (22.5 mg)
Study: 3993320
Drug: Glucose-containing bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing bupivacaine (20 mg)
Study: 3993320
Drug: Tetracaine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine (15 mg)
Study: 30680521
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg once daily
Study: 30129517
Drug: Supervised Structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised Structured Aerobic Exercise Training (SSAET) program, routine medication, and dietary plan for 25 weeks.
Study: 30129517
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication and dietary plan for 25 weeks (Control group).
Study: 25589316
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy including antibiotics, vessels extending drugs, neuroprotective and detoxification facilities.
Study: 25589316
Drug: Cytoflavin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by 2 tablets 2 times a day orally for 1 month in addition to basic therapy.
Study: 20837917
Drug: Intravenous T3
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous T3 as Triostat (n=98)
Study: 19061712
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF) administered at 10 microg/kg SC for 5 days, followed by leukapheresis and randomized double-blinded intracoronary infusion of CD133+ or unselected cells after 3 months
Study: 8651085
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (40 mg subcutaneously per day for 25 days, n=43)
Study: 8651085
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment, n=60)
Study: 1521210
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone (263 patients)
Study: 25967993
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBOT)
Study: 28983968
Drug: Individualized 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized 6-mercaptopurine increments (stepwise increments of additional 25 mg/m2/day starting on days 50 and/or 71)
Study: 28983968
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (oral 6-mercaptopurine 25 mg/m2/day from days 30 to 85)
Study: 26937858
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (n = 62)
Study: 24958315
Drug: Continuous intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intra-articular infusion anesthesia
Study: 24958315
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion anesthesia
Study: 21105289
Drug: Levetiracetam (LV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LV) administered in a fixed dose schedule over 6 days
Study: 15696988
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of 2% zinc sulfate solution
Study: 10591351
Drug: Corticosteroid (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (60 mg methylprednisolone IM and 12 mg dexamethasone IV)
Study: 9088130
Drug: Doxazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin therapy (Group 3, n = 64)
Study: 1651859
Drug: Terbutaline 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1.25 mg
Study: 29340854
Drug: 12 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 sessions of fractionated thulium laser treatment
Study: 29340854
Drug: Post-laser treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-laser treatment application of growth factor (GF) solution
Study: 22323303
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure therapy
Study: 26926656
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure therapy (adherent group)
Study: 25340832
Drug: Ozenoxacin 1%
Normalized name: OZENOXACIN 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 1% cream
Study: 25209521
Drug: Ozenoxacin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 2% cream
Study: 12678340
Drug: NaP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaP (oral sodium phosphate)
Study: 12678340
Drug: PEG (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG (polyethylene glycol electrolyte lavage solution)
Study: 10740542
Drug: Dopexamine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine 1.0 mg kg‐1 over 5 min, followed by an infusion of 2 micrograms kg‐1 min‐1
Study: 1430505
Drug: Dentifrices containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrices containing 15 mg percent xylitol
Study: 3972929
Drug: Hypnotherapy (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotherapy (6 standardized sessions, one hourly session per week)
Study: 31855909
Drug: 12-week single-legged
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week single-legged decline-squat exercise + weekly session of ESWT for 6 weeks
Study: 29940797
Drug: Tele-delivered mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-delivered mindfulness-based cognitive therapy
Study: 23877988
Drug: Sitagliptin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin alone or in combination with glargine insulin
Study: 23877988
Drug: Basal bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal bolus insulin regimen (glargine and lispro) plus supplemental doses of lispro
Study: 20108652
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Bellissima)
Study: 16426094
Drug: Lithium (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (serum concentration 0.6 to 1.2 mEq/L)
Study: 15450048
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (OS) for 3 months
Study: 31853103
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 0.5mg/kg in 5ml
Study: 28013123
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin 40 IU taken four times a day (QID)
Study: 26174460
Drug: Avena sativa
Normalized name: Avena Sativa
DrugBank: Avena sativa flowering top (DB14253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avena sativa lotion, twice a day for 2 weeks
Study: 26174460
Drug: Hydroxyzine tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine tablets, for 2 weeks
Study: 12964648
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received antimicrobial treatment (topical application of NaF and iodine solution) and restorative care using glass ionomer cement.
Study: 12964648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received primary care intervention and oral hygiene kits.
Study: 12964648
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received primary care intervention and oral hygiene kits.
Study: 11518470
Drug: Fibrin-glue coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin-glue coated collagen patch
Study: 9401830
Drug: Carbamazepine 400
Normalized name: carbamazepine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 400 mg retard AWD (test)
Study: 22734586
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) at a fixed dose of 10 mg/kg/day for 18 months
Study: 20371785
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy for 6 months (group 1, n = 183)